The BOARD Framework: Your Treatment Strategy
At a Glance
The BOARD framework is the standard treatment strategy for peripartum cardiomyopathy (PPCM), combining bromocriptine, oral medications, anticoagulants, relaxants, and diuretics. Treatment plans are customized based on pregnancy status and breastfeeding choices to safely heal the heart.
Managing Peripartum Cardiomyopathy (PPCM) requires a proactive and structured approach. The goal is to take the “workload” off your heart so the muscle has the best possible chance to heal [1][2]. Many specialists use the BOARD framework to organize this treatment [3][4].
The BOARD Framework
This acronym represents the five pillars of modern PPCM care:
- B: Bromocriptine
This medication targets the “bad actor” (16kDa prolactin) mentioned on previous pages. It blocks the pituitary gland from releasing prolactin, stopping the production of the toxic fragments [5][6]. While bromocriptine is recommended by some international guidelines (like in Europe) and has been associated with better heart recovery in some studies, it is not universally prescribed and is still being actively studied in clinical trials (such as the REBIRTH trial in the US) [7][8]. Your doctor will discuss if this targeted therapy is right for you. - O: Oral Heart Failure Medications
These are the “gold standard” drugs used to support the heart. They include:- Beta-blockers: To slow the heart rate and lower blood pressure [9].
- ACE Inhibitors / ARBs / Entresto: These relax blood vessels. Note: These are strictly contraindicated (unsafe) during pregnancy. Postpartum, their safety during lactation varies significantly. For example, Entresto is generally unsafe during breastfeeding, whereas certain ACE inhibitors (like enalapril) are considered safe [10][9]. Your care team will select specific lactation-safe medications if you choose to breastfeed.
- MRAs (like Spironolactone): To prevent scarring of the heart muscle [11].
- A: Anticoagulants
PPCM significantly increases your risk of blood clots. Additionally, bromocriptine carries a known, severe risk of strokes and cardiovascular clotting events in postpartum women [12][13]. Because of this serious risk, doctors mandate “blood thinners” (like heparin or Lovenox) alongside bromocriptine to prevent life-threatening clots [12]. - R: Relaxants (Vasodilators)
These drugs (like hydralazine) help “relax” the arteries, making it easier for a weak heart to pump blood forward [3]. - D: Diuretics
Commonly called “water pills,” these help your body get rid of excess fluid that builds up in your lungs and legs, making it much easier for you to breathe [3].
A Note on Breastfeeding and Bromocriptine
Because bromocriptine works by stopping prolactin, taking it will also stop your breast milk production [5][14]. The decision between taking bromocriptine and breastfeeding is highly personal and should be a shared decision-making process with your doctor.
Many women recover fully on standard, breastfeeding-safe heart failure medications without using bromocriptine [15][16]. Your care team will weigh your clinical symptoms, the severity of your heart failure, and your personal preferences regarding lactation to find the safest path forward for both you and your baby.
Adapting Treatment
Your treatment plan must be customized based on where you are in your journey:
- If you are still pregnant: Your doctors will avoid ACE inhibitors and MRAs, focusing on baby-safe alternatives like certain beta-blockers and vasodilators [9][4].
- If you are postpartum: You can typically start the full range of oral medications. If you decide to breastfeed, your doctor will adjust your oral medications to those that are safest for the infant [11][9].
Lifestyle and Home Management
While lifestyle did not cause your PPCM, managing your daily habits helps reduce the workload on your healing heart. Your doctor will likely recommend sodium (salt) restriction and fluid management (limiting how much you drink daily) to prevent excess fluid from backing up into your lungs and legs [3].
Common questions in this guide
What is the BOARD framework for PPCM?
Can I breastfeed while taking medications for peripartum cardiomyopathy?
Why do I need to take blood thinners for PPCM?
Do I need to change my diet while recovering from PPCM?
Questions for Your Doctor
5 questions
- •Is the BOARD framework being used for my treatment, and if not, which parts are we modifying?
- •Are my specific oral heart failure medications safe if I decide to breastfeed, or do we need to switch them?
- •What are the severe clotting risks of my current medication plan, and how are we managing them with anticoagulants?
- •If we discuss using bromocriptine, what is the current evidence supporting it, and what are the specific risks I need to be aware of?
- •How much sodium and fluid should I restrict in my daily diet to help my heart heal faster?
Questions for You
3 questions
- •How am I feeling emotionally about the possibility of having to modify or stop breastfeeding to prioritize my heart health?
- •Who can help me with bottle-feeding and overnight care so I can get the rest my heart needs to heal?
- •Am I keeping a daily log of my weight, fluid intake, and symptoms to report back to my cardiology team?
References
References (16)
- 1
Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry.
Sliwa K, Petrie MC, van der Meer P, et al.
European heart journal 2020; (41(39)):3787-3797 doi:10.1093/eurheartj/ehaa455.
PMID: 32840318 - 2
Heart Transplantation for Peripartum Cardiomyopathy: A Single-Center Experience.
Bouabdallaoui N, Demondion P, Maréchaux S, et al.
Arquivos brasileiros de cardiologia 2018; (110(2)):181-187 doi:10.5935/abc.20180014.
PMID: 29466490 - 3
Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD.
Arrigo M, Blet A, Mebazaa A
European heart journal 2017; (38(35)):2680-2682 doi:10.1093/eurheartj/ehx428.
PMID: 28934838 - 4
Postpartum cardiomyopathy with congestive heart failure: A case report.
Jayte M, Mohamud A, Dubad F
SAGE open medical case reports 2024; (12()):2050313X241263761 doi:10.1177/2050313X241263761.
PMID: 38911174 - 5
Cardiomyopathies and Congenital Heart Disease in Pregnancy.
Westhoff-Bleck M, Hilfiker-Kleiner D, Pankuweit S, Schieffer B
Geburtshilfe und Frauenheilkunde 2018; (78(12)):1256-1261 doi:10.1055/a-0774-8696.
PMID: 30655649 - 6
The regulatory effect of bromocriptine on cardiac hypertrophy by prolactin and D2 receptor modulation.
Aguayo-Cerón KA, Calzada-Mendoza CC, Méndez-Bolaina E, et al.
Clinical and experimental hypertension (New York, N.Y. : 1993) 2020; (42(7)):675-679 doi:10.1080/10641963.2020.1772814.
PMID: 32478610 - 7
Heart failure due to peripartum cardiomyopathy presenting in the first week of puerperium-A case series from Nepal.
Banmala S, Awal S, Bata L, et al.
Clinical case reports 2024; (12(6)):e9043 doi:10.1002/ccr3.9043.
PMID: 38827942 - 8
Efficacy and safety of bromocriptine in peripartum cardiomyopathy: A systematic review and meta-analysis.
Attachaipanich T, Attachaipanich S, Kaewboot K
International journal of cardiology 2025; (427()):133105 doi:10.1016/j.ijcard.2025.133105.
PMID: 40037477 - 9
Peripartum cardiomyopathy and acute heart failure associated with prolonged tocolytic therapy in pregnancy: A case report.
Li PC, Chang HR, Kao SP
Medicine 2021; (100(34)):e27080 doi:10.1097/MD.0000000000027080.
PMID: 34449509 - 10
Peripartum cardiomyopathy.
Jha N, Jha AK
Heart failure reviews 2021; (26(4)):781-797 doi:10.1007/s10741-020-10060-y.
PMID: 33438106 - 11
July 2019 at a glance: imaging of congestion, sodium-glucose co-transporter 2 inhibitors, myocardial function and MitraClip trials.
Metra M
European journal of heart failure 2019; (21(7)):821-822 doi:10.1002/ejhf.1266.
PMID: 31353809 - 12
Anticoagulation for intra-cardiac thrombi in peripartum cardiomyopathy: A review of the literature.
Agrawal A, Jain D, Ram P, et al.
Reviews in cardiovascular medicine 2019; (20(2)):53-58 doi:10.31083/j.rcm.2019.02.55.
PMID: 31344997 - 13
Complete recovery of fulminant peripartum cardiomyopathy on mechanical circulatory support combined with high-dose bromocriptine therapy.
Horn P, Saeed D, Akhyari P, et al.
ESC heart failure 2017; (4(4)):641-644 doi:10.1002/ehf2.12175.
PMID: 28744986 - 14
Peripartum cardiomyopathy: A systematic review of the literature.
Asad ZUA, Maiwand M, Farah F, Dasari TW
Clinical cardiology 2018; (41(5)):693-697 doi:10.1002/clc.22932.
PMID: 29749620 - 15
Management of Heart Failure and Cardiogenic Shock in Pregnancy.
Sharma S, Thomas SS
Current treatment options in cardiovascular medicine 2019; (21(12)):83 doi:10.1007/s11936-019-0797-1.
PMID: 31820124 - 16
Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy.
Pfeffer TJ, Mueller JH, Haebel L, et al.
ESC heart failure 2023; (10(1)):465-477 doi:10.1002/ehf2.14210.
PMID: 36300679
This page provides educational information about the BOARD treatment framework for peripartum cardiomyopathy. Always consult your cardiologist and obstetrician to determine the safest medication plan for both you and your baby.
Get notified when new evidence is published on Peripartum cardiomyopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.